A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Trial Profile

A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs ACH 4471 (Primary) ; Eculizumab
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 26 Mar 2018 Planned initiation date changed from 31 Mar 2018 to 15 Apr 2018.
    • 15 Mar 2018 Status changed from planning to not yet recruiting.
    • 12 Feb 2018 According to an Achillion media release, interim data from this study is expected in fourth quarter 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top